19:31 , Feb 7, 2019 |  BC Extra  |  Tools & Techniques

Virtual compound library for high throughput computational drug discovery

University of California San Francisco researchers have launched an updated, publicly available and growing virtual library of over 350 million small molecules, all of which can be synthesized on demand. Combined with high throughput computational...
13:06 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

Merck & Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III ASPECT-NP trial to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Zerbaxa was non-inferior to meropenem in...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Additional Phase III data

Additional pooled data from 993 patients with cIAIs in a pair of identical, double-blind, double-dummy, international Phase III trials showed that 1.5 g IV ceftolozane/tazobactam every 8 hours plus 0.5 g IV metronidazole for 4-14...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Additional Phase III data

Additional pooled data from 1,083 patients with cUTI in a pair of identical, double-blind, international Phase III trials showed that 1.5 g IV ceftolozane/tazobactam every 8 hours for 7 days led to a composite cure...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Phase III data

Last month, Cubist reported that IV ceftolozane/tazobactam met the FDA- and EMA-defined primary endpoints of non-inferiority to IV levofloxacin in a pair of identical Phase III trials to treat complicated urinary tract infection (cUTI) (see...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Phase III data

Cubist expects to report top-line data late this month from a pair of Phase III trials evaluating ceftolozane/tazobactam to treat complicated intra-abdominal infections (cIAI). Cubist plans to submit an NDA to FDA in 1H14 and...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Phase III started

Cubist began the open-label, U.S. and Australian Phase III VECTOR trial comparing 3,000 mg IV ceftolozane/tazobactam every 8 hours vs. 4,500 mg piperacillin/tazobactam every 6 hours in about 300 patients. The product is in Phase...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

CXA-201: Phase III started

Cubist began a double-blind, double-dummy, international Phase III trial to compare 1,500 mg IV CXA-201 every 8 hours in combination with 500 mg IV metronidazole every 8 hours for 4-14 days vs. 1,000 IV meropenem...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

CXA-201: Phase III started

Cubist began a double-blind, international Phase III trial to compare 1,500 mg IV CXA-201 given every 8 hours for 7 days vs. IV levofloxacin in about 775 patients. The company expects to begin a second...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

CXA-201: Phase II data

Top-line data from a double-blind, international Phase II trial in 122 patients showed that 1.5 g thrice-daily IV CXA-201 plus metronidazole led to a comparable clinical cure rate at the TOC visit 7-14 days after...